Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06888102 · ClinicalTrials.gov registry record · Early Phase 1
A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer
A Early Phase 1 study of High-risk Prostate Cancer, sponsored by Edwin Posadas, MD.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06888102 is a Early Phase 1 study of High-risk Prostate Cancer that is actively recruiting participants, run by Edwin Posadas, MD. The registered enrollment target is 20 participants, below the 54-participant average among 4 other High-risk Prostate Cancer trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06888102, a Early Phase 1 study of High-risk Prostate Cancer, is actively recruiting participants, sponsored by Edwin Posadas, MD.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of epigenetic therapies in participants with localized prostate cancer who are undergoing radical prostatectomy. The epigenetic therapy is intended to increase the sensitivity of the underlying tumor to the patient's immune system. The platform study will evaluate safety, biomarkers, and clinical activity of an epigenetic therapy. The particular details relevant to each module within this platform study will be provided as appendices to the core protocol.
Conditions Studied
Interventions
- DRUG Neoadjuvant Epigenetic Therapy
Study Locations (1)
California
- Cedars-Sinai Cancer at SOCC - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-04 |
| Est. Completion | 2029-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06888102
The ClinicalTrials.gov registry entry for NCT06888102 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 54-participant average among 4 other High-risk Prostate Cancer trials with a reported enrollment target (63% lower). The listed sponsor is Edwin Posadas, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High-risk Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Neoadjuvant Epigenetic Therapy is the first listed.
NCT06888102 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06888102 about?
NCT06888102 is a clinical study titled "A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer". This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of epigenetic therapies in participants with localized prostate cancer who are undergoing radical prostatectomy. The epigenetic therapy is intended to increase the sensitivity of...
What is the current status of trial NCT06888102?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2026-04. Estimated completion is 2029-10.
What conditions does trial NCT06888102 study?
This clinical trial studies the following conditions: High-risk Prostate Cancer.
What interventions are being tested in trial NCT06888102?
The interventions under investigation include: Neoadjuvant Epigenetic Therapy (DRUG).
Who is sponsoring clinical trial NCT06888102?
This trial is sponsored by Edwin Posadas, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06888102 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High-risk Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
RECRUITING · Phase 1
-
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.